First-in-Human

Mark Cappucci

Mark Cappucci serves as the Preformulation Team Lead at Lonza's site in Tampa, Florida, USA. He has more than 23 years of experience in the pharmaceutical industry, with expertise in areas including drug substance characterization, polymorph identification, and microdosing techniques using Lonza's Xcelodose® system. Mark joined Lonza in 2004, after working for Amgen and Bausch & Lomb in positions of increasing authority. He received his B.S. in Chemistry from The Ohio State University.

Watch interview

Meet Mark

Want to learn how our Lonza Tampa site allows customers to "leave their drug substance at the door"? Find out more from Mark in this short video.

Content by this expert

Recently published by Mark

Whitepaper/Executive Summary

First-In-Human to Commercial: A Microdosing Journey

This executive summary will explore the benchmark practices for rapid progression from...

Microdosing graphic

Webinar (on-demand)

First-in-Human To Commercial: A Microdosing Journey

These webinar slides explore the benchmark practices for rapid progression from First-in-Human to...

SM-Commercial-Drug-Product

Presentation (on-demand)

Powder in Capsule: A Way to Accelerate Drug Product Development by Technologies

The Powder in Capsule (PIC) approach by means of micro-dosing provides an alternative pathway for...

Webinar (on-demand)

Drug Product Advancement - A Path Through Development by Powder in Capsule Approach

Using micro-dosing technology and powder-in-capsule (PIC) or powder-in-bottle (PIB) approaches,...